Sign in8 stories
New preclinical data show sabizabulin overcomes resistance to Revolution Medicines' daraxonrasib, prompting Veru to drop a cardiovascular indication and pursue an FDA preIND meeting in Q4 2026.
SEC filing
The company signed leases for about 672,000 square feet across four Seaport Boulevard buildings, with commencement contingent on the landlord's acquisition of the properties.
SEC filing
FDA accepted the pancreatic cancer NDA and granted Breakthrough Therapy status in NSCLC as the company posted a $644.4 million quarterly net loss.
SEC filing
Summit Therapeutics posted $690.7 million in cash at quarter end and highlighted updated HARMONi survival data ahead of a November 14, 2026 FDA decision on ivonescimab.
SEC filing (2)